Merck, GSK, BIO and Pew Comment on Draft Guidance on LPAD Approval Pathway

Merck, GSK, BIO and Pew Comment on Draft Guidance on LPAD Approval Pathway

Submitted by admin on August 15, 2018 - 10:30pm
Source: 
RAPS.org
News Tags: 
Merck
GSK
BIO
Pew Charitable Trusts
LPAD pathway
Headline: 
Merck, GSK, BIO and Pew Comment on Draft Guidance on LPAD Approval Pathway
snippet: 

Merck, GlaxoSmithKline, BIO and Pew Charitable Trusts weighed in on recent draft guidance on the establishment of a limited population pathway for antibacterial and antifungal drugs (LPAD pathway).

Do Not Allow Advertisers to Use My Personal information